Early progress doesn't always equal long-term success. But at least in the case of Teva Pharmaceutical Industries--which is firing on all cylinders to convert patients to a new, long-acting version of Copaxone--early results have some analysts thinking the Israeli company may deliver on its promise to switch 30% to 50% of patients.
Teva Pharmaceutical Industries is trying to throw up yet another hurdle to a generic version of its blockbuster multiple sclerosis drug Copaxone from India's Natco Pharmaceuticals.
Teva doesn't have much time left to switch patients over to its new, thrice-weekly Copaxone injection before generics jump on the current product. And while the company is working feverishly to market its new drug to patients, insurers may be the most difficult to persuade.
At least one key investor seems to think Teva is headed in the right direction. Billionaire George Soros boosted his family office's stake in the Israeli company in the last quarter of 2013, adding 5.7 million shares to make the Israeli generics giant its largest holding.
Teva Pharmaceutical Industries is like a skiff-racing team that's beating its own speed records on the river but heading for an enormous waterfall just around the bend. As well as it performs now, the question remains: How well can it recover from the imminent loss of Copaxone patent protection?
Brace yourselves for the Teva Pharmaceutical Industries marketing blitz. The company won FDA approval Tuesday evening for its new, three-times-a-week Copaxone, and Teva needs to convert as many patients as possible to the new version before the original goes off patent in May.
Teva Pharmaceutical Industries is making one last desperate plea to the U.S. Supreme Court. The Israel-based drugmaker has asked SCOTUS to review a lower court's decision to invalidate key patents on its top-selling drug, Copaxone.
Generic competition for its top-selling Copaxone drug will hit Teva Pharmaceutical Industries hard. Now, we know just how hard--at least according to Teva itself. The company expects sales and operating profits to come in $550 million lighter next year if copies of the multiple sclerosis treatment make it to market.
Teva's best-selling drug Copaxone will face generic competition next year, fully 18 months before the company had anticipated. That's gonna hurt. How much will it hurt? An Israeli publication thinks it has Teva's answer to that--a 42% cut to the drug's sizable profits.
Teva Pharmaceutical Industries took another shot at fending off early generic competition for its top-selling drug Copaxone. But the U.S. Supreme Court didn't cooperate. The court refused to stay a Federal Circuit ruling that would allow generic rivals onto the market next May, 18 months earlier than Teva had anticipated.